Drug Profile
Anti-CD19 chimeric antigen receptor T cell therapy - Shenzhen Innovation Immunotechnology
Latest Information Update: 29 Sep 2020
Price :
$50
*
At a glance
- Originator Shenzhen Innovation Immunotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haematological malignancies
Most Recent Events
- 29 Sep 2020 Phase-I/II development in Haematological malignancies is ongoing in China (ChiCTR-OIC17013633)
- 12 Jan 2017 Phase-I/II clinical trials in Haematological malignancies (In adults, In adolescents, In children, In infants) in China (IV) (ChiCTR-OIC17013633)